616 studies found for:    "melphalan"
Show Display Options
Rank Status Study
1 Active, not recruiting Busulfan Plus Melphalan Versus Melphalan
Condition: Myeloma
Interventions: Drug: Busulfan;   Drug: Melphalan;   Other: Questionnaire;   Drug: G-CSF;   Drug: High Dose Melphalan;   Procedure: Stem cell transplant
2 Terminated Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage
Condition: Retinoblastoma
Intervention: Drug: Melphalan
3 Active, not recruiting Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Conditions: Primary Systemic Amyloidosis;   Light Chain Deposition Disease
Interventions: Drug: bortezomib;   Drug: dexamethasone;   Drug: melphalan;   Genetic: microarray analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
4 Active, not recruiting
Has Results
Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.
Condition: Multiple Myeloma
Interventions: Drug: melphalan;   Drug: topotecan (TPT);   Procedure: Autologous Stem Cell Rescue
5 Terminated Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Conditions: Light Chain Deposition Disease;   Primary Systemic Amyloidosis
Interventions: Drug: melphalan;   Drug: dexamethasone;   Drug: bortezomib
6 Active, not recruiting Lenalidomide and High-Dose Melphalan
Conditions: Myeloma;   Stem Cell Transplantation
Interventions: Drug: Lenalidomide;   Drug: Melphalan;   Procedure: Stem Cell Infusion
7 Recruiting Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
Condition: Myeloma
Interventions: Drug: Pomalidomide;   Drug: Melphalan;   Drug: Dexamethasone;   Behavioral: Questionnaires
8 Active, not recruiting
Has Results
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: melphalan;   Drug: amifostine trihydrate;   Procedure: peripheral blood stem cell transplantation;   Genetic: fluorescence in situ hybridization;   Procedure: bone marrow ablation with stem cell support
9 Recruiting Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment
Condition: Regional Melanoma
Interventions: Drug: Melphalan;   Drug: Tropisetron;   Drug: Morphine
10 Terminated Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma
Condition: Newly Diagnosed, Multiple Myeloma
Interventions: Drug: Thalidomide;   Drug: melphalan, prednisone;   Drug: melphalan, prednisone, thalidomide
11 Recruiting Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: fludarabine phosphate;   Other: melphalan;   Radiation: total marrow irradiation;   Drug: tacrolimus;   Drug: sirolimus;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
12 Completed TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Topotecan;   Drug: Cyclophosphamide;   Drug: Melphalan;   Other: Peripheral Blood Stem Cells
13 Completed Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Melphalan
14 Recruiting High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
Condition: Lymphoma
Interventions: Drug: Gemcitabine;   Drug: Busulfan;   Drug: Melphalan;   Procedure: Stem Cell Transplantation;   Drug: Palifermin
15 Completed Melphalan & Palifermin Followed by Peripheral Blood Stem Cell Transplant in Treating Pts w/Stage II-III Multiple Myeloma
Conditions: Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: melphalan;   Biological: palifermin;   Procedure: peripheral blood stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation
16 Recruiting Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Radiation: total-body irradiation;   Drug: melphalan;   Procedure: autologous bone marrow transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
17 Recruiting Microdose Study of Melphalan, Bortezomib and Dexamethasone
Condition: Multiple Myeloma
Interventions: Drug: Melphalan;   Drug: Bortezomib;   Drug: Dexamethasone
18 Active, not recruiting Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: autologous bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Biological: therapeutic allogeneic lymphocytes
19 Recruiting Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Previously Treated Myelodysplastic Syndromes;   Secondary Acute Myeloid Leukemia
Interventions: Drug: clofarabine;   Drug: melphalan;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis;   Drug: tacrolimus;   Drug: sirolimus
20 Active, not recruiting Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Melphalan, Prednisone, Lenalidomide;   Drug: Cyclophosphamide, Prednisone, Lenalidomide;   Drug: Lenalidomide, dexamethasone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years